Immunoscape and mink therapeutics collaborate to accelerate novel tcr identification and therapeutic development

San diego and new york and singapore, dec. 20, 2023 (globe newswire) -- immunoscape , a biotechnology company focused on the discovery and development of next-generation t cell receptor (tcr)-based therapeutics, and mink therapeutics , inc (nasdaq: inkt), a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell targeting therapies, today announced a collaboration agreement to discover and develop next-generation tcr therapies against novel targets in solid tumors. the combined efforts of both companies aim to accelerate the development of tcr-based therapies against novel targets in t cells, inkt cells, and other modalities, potentially offering new therapeutic approaches for diverse cancer indications.
INKT Ratings Summary
INKT Quant Ranking